MSI-H/dMMR

News alerts, weekly reports and conference planners

Related biomarkers:

Expression

Mutation

Others

‹

›

Related tests:

FoundationOne® CDx (110)

MI Cancer Seek™

FoundationOne® CDx (110)

MI Cancer Seek™

MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1	dostarlimab-gxly Sensitive: A1 - Approval dostarlimab-gxly Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1
MSI-H/dMMR	Solid Tumor	MSI-H/dMMR	Solid Tumor	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
MSI-H/dMMR	Peritoneal Cancer	MSI-H/dMMR	Peritoneal Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
MSI-H/dMMR	Colon Cancer	MSI-H/dMMR	Colon Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Fallopian Tube Cancer	MSI-H/dMMR	Fallopian Tube Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Maxillary Sinus Carcinoma	MSI-H/dMMR	Maxillary Sinus Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Penile Cancer	MSI-H/dMMR	Penile Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Endometrial Cancer	MSI-H/dMMR	Endometrial Cancer	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2	pembrolizumab + lenvatinib Sensitive: A2 - Guideline pembrolizumab + lenvatinib Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Small Intestinal Carcinoma	MSI-H/dMMR	Small Intestinal Carcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
MSI-H/dMMR	Ovarian Cancer	MSI-H/dMMR	Ovarian Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Gastric Cancer	MSI-H/dMMR	Gastric Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
MSI-H/dMMR	Germ Cell Tumors	MSI-H/dMMR	Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	MSI-H/dMMR	Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2	pembrolizumab + ipilimumab Sensitive: A2 - Guideline pembrolizumab + ipilimumab Sensitive : A2

MSI-H/dMMR

Associations